A$ 1.38
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong growth
About
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of PNV.AX is 2.1 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
